Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2007, Pages 383-391

  Enriquez, A D ^a   Campbell, M S ^a   Reddy, K R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DNA VIRUS; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH STATUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SEROCONVERSION; STATISTICAL ANALYSIS; VIREMIA;

CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MODELS, THEORETICAL; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 34447340970     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03382.x     Document Type: Article

References (52)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997 337 : 1733 45.
2. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1998 61 : 1942 56.
3. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In : Wilson RA, ed. Viral Hepatitis. New York : Marcel Dekker, 1997 : 315 30.
4. Lok AF, McMahon BJ. AASLD Practice Guidelines: Chronic Hepatitis B. Available at: http://www.aasld.org 2003 : 1 25.
5. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984 13 : 385 91.
6. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987 92 : 39 43.
7. Do S. The natural history of hepatitis B in Asian Americans. Asian Am Pac Isl J Health 2001 Summer-Fall : 141 53.
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 86.
10. Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004 351 : 15.
11. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 354 : 1001 10.
12. Honkoop P, De Man RA, Niesters HGM, et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution PCR in chronic hepatitis B patients. J Viral Hepat 1998 5 : 307 12.
13. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005 129 : 528 36.
14. Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005 100 : 2463 71.
15. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005 352 : 2682 95.
16. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000 32 : 847 51.
17. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 : 1256 63.
18. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000 119 : 172 80.
19. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment with chronic hepatitis B enhances HBeAg seroconversion rates: results after 3 years of therapy. Hepatology 2001 33 : 1527 32.
20. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001 34 : 785 91.
21. Lok AF, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 : 1714 22.
22. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998 339 : 61 8.
23. Lau DTY, Khokar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000 32 : 828 34.
24. Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003 52 : 416 9.
25. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BMR. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 31.
26. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg positive patients treated with interferon alfa for chronic hepatits B. N Engl J Med 1996 334 : 1422 7.
27. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for HBeAg seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999 30 : 770 4.
28. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002 36 : 186 94.
29. Bruix J, Sherman M. AASLD practice guidelines: management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 36.
30. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003 362 : 1907 17.
31. Chan HLK, Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006 26 : 153 61.
32. Surveillance Epidemiology and End Results registry. Available at: http://seer.cancer.gov. Accessed Oct 2006.
33. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977-1996 in the United States. Hepatology 2001 33 : 62 5.
34. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 : S27 34.
35. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 2006 26 : 142 52.
36. Fattovich G, Giustina G, Realdi G, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995 21 : 77 82.
37. Chen T, Luk JM, Cheung ST, Yu WC, Fan ST. Evaluation of quantitative PCR and branched-chain DNA assay for detection of hepatitis B virus DNA in sera from hepatocellular carcinoma and liver transplant patients. J Clin Microbiol 2000 38 : 1977 80.
38. Lee T, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004 38 : S144 7.
39. Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998 28 : 436 42.
40. Chong CAKY, Gulamhussein A, Heathcote JE, et al. Health-State utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003 98 : 630 8.
41. Owens DK, Cardinalli AB, Nease RF Jr. Physicians' assessments of the utility of health states associated with HIV and HBV infection. Qual Life Res 1997 6 : 77 86.
42. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005 100 : 643 51.
43. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000 20 : 451 67.
44. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004 116 : 829 34.
45. Yang PM, Chen DS, Lai MY, et al. Clinicopathologic studies of asymptomatic HBsAg carriers: with special emphasis on carriers older than 40 years. Hepatogastroenterology 1987 34 : 251 4.
46. Lin X, Robinson NJ, Thursz M, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005 20 : 833 43.
47. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005 10 : 431 9.
48. Korba BE, Cote PJ, Menne S, et al. Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection. Antivir Ther 2004 9 : 937 52.
49. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001 184 : 1236 45.
50. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 37 : 748 55.
51. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002 36 : 219 26.
52. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006 101 : 2076 89.